Sensei Biotherapeutics, Inc. announced it will present initial safety and pharmacokinetic monotherapy clinical data from its Phase 1/2 trial of SNS- 101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), in a late-breaking poster presentation at the Society for Immunotherapy of Cancer (SITC) 38(th) Annual Meeting, being held in San Diego, Calif., from November 1 - 5, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.57 USD | -14.67% | -4.85% | +126.88% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+126.88% | 46.15M | |
+2.97% | 108B | |
+10.21% | 105B | |
+1.57% | 23.46B | |
-12.77% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.50% | 17.19B | |
+6.00% | 13.99B | |
+37.20% | 12.53B |
- Stock Market
- Equities
- SNSE Stock
- News Sensei Biotherapeutics, Inc.
- Sensei Biotherapeutics, Inc. to Present Initial Clinical Data from Dose Escalation Trial of SNS 101 At 2023 SITC Annual Meeting